Alzheimer's patients will need to have a brain scan showing the presence of beta-amyloid in order to receive Biogen's Aduhelm (aducanumab) treatment, yet Medicare doesn't cover such exams.

Absent passage of HR 3657, the profession is “in peril,” with RAs losing their jobs and left unable to practice to the full extent of their training, advocates said. 

The two tech giants have now cleared a key hurdle to completing their merger, company officials revealed recently. 

Pylarify is a F 18-labeled, prostate-specific membrane antigen targeted PET agent used to pinpoint suspected metastasis or recurrence of the disease. 

Most nonhospital-based groups fall outside of the new CMS rule, but there’s still an opportunity to adopt this mindset and attract new customers, experts wrote recently. 

This is the FDA's second mammography warning in two days, with both centers going weeks without performing mandatory quality-control tests.

Rad involvement in these value-minded care-coordination efforts leapt threefold, preparing members of the specialty to take on downside risk while strengthening bonds with hospital partners.

CMS recently postponed the go-live date of the Medicare Coverage Innovative Technology rule for the second time.